Research Overview

CJC-1295 / Ipamorelin

CJC-1295 and Ipamorelin (GH secretagogue research combination)

A GHRH analog and a selective ghrelin-receptor agonist, frequently studied together as a GH-axis combination.

What It Is

CJC-1295 (the No-DAC variant sold by unrl) is a synthetic analog of growth-hormone-releasing hormone (GHRH), engineered with amino-acid substitutions that give it greater stability against enzymatic degradation than native GHRH. Ipamorelin is a separate, structurally distinct pentapeptide classified as a selective ghrelin-receptor (GH secretagogue receptor) agonist.

The two are frequently studied together in the growth-hormone-axis literature because they act on two different receptor systems that converge on the same downstream output, which is why researchers describing GH-axis pharmacology often reference them as a pair rather than in isolation.

Mechanism in the Research Literature

CJC-1295 is reported to bind the GHRH receptor on pituitary somatotrophs, the pathway responsible for pulsatile growth hormone release. Ipamorelin's studied mechanism is agonism at the ghrelin/GH-secretagogue receptor, a separate receptor system also implicated in GH release, distinguished in the literature by its selectivity: research has reported minimal effect on cortisol, prolactin, or acetylcholine compared to older secretagogues in the same class.

Because the two compounds act through independent receptor pathways that converge on GH output, in vitro and in vivo research has examined their combined signaling as a model for studying receptor-pathway convergence in the GH axis.

Why Purity Verification Matters Here

Both CJC-1295 and Ipamorelin are receptor-agonist peptides, meaning their activity in an assay depends on an intact binding domain. Degradation products or synthesis impurities can act as weak partial agonists or antagonists at the same receptor, confounding a dose-response curve without any obvious sign in the vial. Independent HPLC/mass-spec verification per lot is the only way to rule this out before running a receptor-binding or GH-release assay.

Third-party tested. Lot-matched. No exceptions.

Every unrl batch is characterized by independent third-party testing before it ships, not just an in-house spec sheet. Each Certificate of Analysis is tied to the lot number printed on the vial, so what you're holding matches a specific, published result rather than a generic average.

Independent lab, not manufacturer self-testing
HPLC purity + mass spectrometry identity confirmation
Lot-specific CoA, matched to the vial in hand
Published and searchable in the public COA library

View the COA Library

Research Use Only

This page is provided for research and educational purposes only. The compound discussed is a research reference standard, not a dietary supplement, drug, or article for human or veterinary use. Nothing on this page is medical advice, dosing guidance, or a claim of safety or efficacy. No statement has been evaluated by the FDA.

Quick Reference

Classification: GHRH analog (CJC-1295) + selective ghrelin-receptor agonist (Ipamorelin)
Receptor systems: GHRH receptor; ghrelin / GH-secretagogue receptor
Common research models: Pituitary cell culture, GH-axis pharmacology
Distinguishing feature: Reported receptor selectivity (Ipamorelin) vs. older secretagogues